# US 2025/0152553 A1 · Carbamothioate, and carbamodithioate derivatives of mdma, mda or its optically active (r)- or (s)-mdma and mda isomers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152553 A1
- Document ID: US20250152553A1
- Status: Published application
- Kind: A1
- Application number: 18/934,442
- Filed: 2024-11-01
- Published: 2025-05-15
- Earliest claimed: 2023-11-03
- Applicants: EmpathBio, Inc.
- Inventors: Tanweer A. KHAN; Glenn SHORT; Robert B. PERNI
- Web page: https://patentgrep.com/patent/US20250152553A1

## CPC

- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- C07D 317/58: Radicals substituted by nitrogen atoms (nitro radicals C07D317/52)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided herein are carbamothioate and carbamodithioate derivates of 3,4-methylenedioxymethamphetamine, (R)-3,4-methylenedioxymethamphetamine and (S)-3,4-methylenedioxymethamphetamine.

## Claims

### Claim 1

A compound of Formula (VI):
wherein X1 and X2 are independently O, S, or N;
R1, R2, R3, and R4 are independently hydrogen, deuterium, alkyl, deuterated alkyl, CH2D, CHD2, CD3, cycloalkyl, halogen, heteroatom-substituted or halogen-substituted alkyl or cycloalkyl, aryl, or heteroaryl; and
R5 and R6, are independently hydrogen, deuterium, CH2D, CHD2, CD3, or a C1 to C6 alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein X2 is S.

### Claim 3 (depends on 2)

The compound of claim 2, wherein X1 is O.

### Claim 4 (depends on 2)

The compound of claim 2, wherein X1 is S.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R2, R3, R4, and R6 are hydrogen or deuterium.

### Claim 6 (depends on 5)

The compound of claim 5, wherein R1 is methyl.

### Claim 7 (depends on 6)

The compound of claim 6, wherein R5 is methyl.

### Claim 8 (depends on 5)

The compound of claim 5, wherein R1 is ethyl.

### Claim 9 (depends on 5)

The compound of claim 5, wherein R1 is propyl.

### Claim 10 (depends on 9)

The compound of claim 9, wherein R1 is isopropyl.

### Claim 11 (depends on 5)

The compound of claim 5, wherein R5 is ethyl.

### Claim 12 (depends on 1)

The compound of claim 1, wherein R6 is methyl.

### Claim 13 (depends on 1)

The compound of claim 1, wherein R1 and R2 combine to form a 3-6 membered cycloalkyl.

### Claim 14 (depends on 13)

The compound of claim 13, wherein R1 and R2 combine to form a 3 membered ring.

### Claim 15 (depends on 13)

The compound of claim 13, wherein R1 and R2 combine to form a 4 membered ring.

### Claim 16 (depends on 13)

The compound of claim 13, wherein R1 and R2 combine to form a 5 membered ring.

### Claim 17 (depends on 13)

The compound of claim 13, wherein R1 and R2 combine to form a 6 membered ring.

### Claim 18 (depends on 1)

The compound of claim 1, wherein R1 is a halogenated alkyl.

### Claim 19 (depends on 1)

The compound of claim 1, wherein R3 and R4 are halogens.

### Claim 20 (depends on 1)

The compound of claim 1, wherein R1 is an ether.

### Claim 21 (depends on 1)

The compound of claim 1, wherein the compound is an R enantiomer.

### Claim 22 (depends on 1)

The compound of claim 1, wherein the compound is an S enantiomer.

### Claim 23 (depends on 1)

The compound of claim 1, wherein the compound persists through a first pass metabolism of a mammal.

### Claim 24 (depends on 23)

The compound of claim 23, wherein the compound acts as a partial agonist of a CNS serotonin receptor.

### Claim 25

A composition comprising a pharmaceutical carrier and a compound of Formula (VI):
wherein X1 and X2 are independently O, S, or N;
R1, R2, R3, and R4 are independently hydrogen, deuterium, alkyl, deuterated alkyl, CH2D, CHD2, CD3, cycloalkyl, halogen, heteroatom-substituted or halogen-substituted alkyl or cycloalkyl, aryl, or heteroaryl; and
R5 and R6, are independently hydrogen, deuterium, methyl, ethyl, CH2D, CHD2, CD3, or a C1 to C6 alkyl.

### Claim 26 (depends on 25)

The composition of claim 25, wherein X2 is S.

### Claim 27 (depends on 26)

The composition of claim 26, wherein X1 is O.

### Claim 28 (depends on 26)

The composition of claim 26, wherein X1 is S.

### Claim 29 (depends on 25)

The composition of claim 25, wherein R2, R3, R4, and R6 are hydrogen or deuterium.

### Claim 30 (depends on 29)

The composition of claim 29, wherein R1 is methyl.

### Claim 31 (depends on 30)

The composition of claim 30, wherein R5 is methyl.

### Claim 32 (depends on 29)

The composition of claim 29, wherein R1 is ethyl.

### Claim 33 (depends on 29)

The composition of claim 29, wherein R1 is propyl.

### Claim 34 (depends on 33)

The composition of claim 33, wherein R1 is isopropyl.

### Claim 35 (depends on 25)

The composition of claim 25, wherein R5 is ethyl.

### Claim 36 (depends on 25)

The composition of claim 25, wherein R6 is methyl.

### Claim 37 (depends on 25)

The composition of claim 25, wherein R1 and R2 combine to form a 3-6 membered cycloalkyl.

### Claim 38 (depends on 37)

The composition of claim 37, wherein R1 and R2 combine to form a 3 membered ring.

### Claim 39 (depends on 37)

The composition of claim 37, wherein R1 and R2 combine to form a 4 membered ring.

### Claim 40 (depends on 37)

The composition of claim 37, wherein R1 and R2 combine to form a 5 membered ring.

### Claim 41 (depends on 37)

The composition of claim 37, wherein R1 and R2 combine to form a 6 membered ring.

### Claim 42 (depends on 25)

The composition of claim 25, wherein R1 is a halogenated alkyl.

### Claim 43 (depends on 25)

The composition of claim 25, wherein R3 and R4 are halogens.

### Claim 44 (depends on 25)

The composition of claim 25, wherein R1 is an ether.

### Claim 45 (depends on 25)

The composition of claim 25, wherein the compound is an R enantiomer.

### Claim 46 (depends on 25)

The composition of claim 25, wherein the compound is an S enantiomer.

### Claim 47 (depends on 25)

The composition of claim 25, wherein the compound persists through a first pass metabolism of a mammal.

### Claim 48 (depends on 47)

The composition of claim 47, wherein the compound acts as a partial agonist of a CNS serotonin receptor.

### Claim 49 (depends on 25)

The composition of claim 25, wherein the pharmaceutical carrier is a bulking agent.
